316 related articles for article (PubMed ID: 35159070)
1. Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer.
Powrózek T; Ochieng Otieno M
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159070
[TBL] [Abstract][Full Text] [Related]
2. Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer.
Di Agostino S; Vahabi M; Turco C; Fontemaggi G
Noncoding RNA; 2022 Jan; 8(1):. PubMed ID: 35076579
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
4. Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer.
Tian T; Zhao Y; Zheng J; Jin S; Liu Z; Wang T
Mol Ther Nucleic Acids; 2021 Dec; 26():63-80. PubMed ID: 34513294
[TBL] [Abstract][Full Text] [Related]
5. Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
Xia M; Zu X; Chen Z; Wen G; Zhong J
Cancer Lett; 2021 Dec; 523():100-110. PubMed ID: 34601022
[TBL] [Abstract][Full Text] [Related]
6. An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer.
Tierno D; Grassi G; Zanconati F; Bortul M; Scaggiante B
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675313
[TBL] [Abstract][Full Text] [Related]
7. Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Ritter A; Hirschfeld M; Berner K; Rücker G; Jäger M; Weiss D; Medl M; Nöthling C; Gassner S; Asberger J; Erbes T
Int J Oncol; 2020 Jan; 56(1):47-68. PubMed ID: 31789396
[TBL] [Abstract][Full Text] [Related]
8. Progress of non-coding RNAs in triple-negative breast cancer.
Liu J; Zhao G; Liu XL; Zhang G; Zhao SQ; Zhang SL; Luo LH; Yin DC; Zhang CY
Life Sci; 2021 May; 272():119238. PubMed ID: 33600860
[TBL] [Abstract][Full Text] [Related]
9. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
10. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.
Shang M; Chang C; Pei Y; Guan Y; Chang J; Li H
J Cancer; 2018; 9(24):4627-4634. PubMed ID: 30588246
[TBL] [Abstract][Full Text] [Related]
11. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
12. Long Non Coding RNA in Triple Negative Breast Cancer: A Promising Biomarker in Tumorigenesis.
Nandagopal S; Misra S; Sankanagoudar S; Banerjee M; Sharma P; Pane SE; Guerriero G; Shukla KK
Asian Pac J Cancer Prev; 2023 Jan; 24(1):49-59. PubMed ID: 36708551
[TBL] [Abstract][Full Text] [Related]
13. Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach.
Shoukat I; Mueller CR
Expert Rev Mol Diagn; 2023 Jan; 23(1):41-51. PubMed ID: 36715539
[TBL] [Abstract][Full Text] [Related]
14. MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review.
Volovat SR; Volovat C; Hordila I; Hordila DA; Mirestean CC; Miron OT; Lungulescu C; Scripcariu DV; Stolniceanu CR; Konsoulova-Kirova AA; Grigorescu C; Stefanescu C; Volovat CC; Augustin I
Front Oncol; 2020; 10():526850. PubMed ID: 33330019
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of serum exosomal SUMO1P3 predicts unfavorable prognosis in triple negative breast cancer.
Na-Er A; Xu YY; Liu YH; Gan YJ
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):154-160. PubMed ID: 33506903
[TBL] [Abstract][Full Text] [Related]
16. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA-associated ceRNA network involved in HIF-1 signalling in triple-negative breast cancer: circ_0047303 as a potential key regulator.
Darbeheshti F; Mahdiannasser M; Noroozi Z; Firoozi Z; Mansoori B; Daraei A; Bastami M; Nariman-Saleh-Fam Z; Valipour E; Mansoori Y
J Cell Mol Med; 2021 Dec; 25(24):11322-11332. PubMed ID: 34791795
[TBL] [Abstract][Full Text] [Related]
18. LncRNA T376626 is a promising serum biomarker and promotes proliferation, migration, and invasion via binding to LAMC2 in triple-negative breast cancer.
He Y; Xiao B; Lei T; Xuan J; Zhu Y; Kuang Z; Liu J; He J; Li L; Sun Z
Gene; 2023 Apr; 860():147227. PubMed ID: 36709879
[TBL] [Abstract][Full Text] [Related]
19. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Circ_0000977-Mediated Regulatory Network in Breast Cancer: A Potential Discriminative Biomarker for Triple-Negative Tumors.
Darbeheshti F; Mansoori Y; Azizi-Tabesh G; Zolfaghari F; Kadkhoda S; Rasti A; Rezaei N; Shakoori A
Biochem Genet; 2023 Aug; 61(4):1487-1508. PubMed ID: 36645554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
